Skip to main content

Table 1 Baseline characteristics of the study population

From: High urinary interleukin-2 in late post-transplant period portends a risk of decline in kidney allograft function: a preliminary study

Parameter Patient groups
eGFR at baseline eGFR decline by 25% at 2 years
Normal eGFR, ≥ 60 mL/min/1.73 m2 (N = 7) Low eGFR, < 60 mL/min/1.73 m2 (N = 23) p No (N = 23) Yes (N = 7) p
Recipient age, years 36 (16–47)a 38 (29–42) 0.565 36 (24–42) 38 (27–42) 0.962
Recipient gender, males, n (%) 2 (28.6) 14 (60.9) 0.134 13 (56.5) 3 (42.9) 0.526
Calcineurin inhibitor, cyclosporine A use, n (%) 5 (71.4) 13 (56.5) 0.481 15 (65.2) 3 (42.9) 0.290
Antiproliferative agent, mycophenolate mofetil use, n (%) 6 (85.7) 23 (100) 0.065 22 (95.7) 7 (100) 0.575
Anti-IL-2 receptor antibodies use, n (%) 5 (71.4) 15 (65.2) 0.760 17 (73.9) 3 (42.9) 0.127
Type of donor, deceased, n (%) 4 (57.1) 18 (78.3) 0.269 16 (69.6) 6 (85.7) 0.398
Impaired initial function, n (%) 1 (14.3) 6 (26.1) 0.518 4 (17.4) 3 (42.9) 0.163
Previous AR, n (%) 0 2 (8.7) 0.419 1 (4.4) 1 (14.3) 0.356
Time after transplantation (months) 68 (45–128) 68 (41–102) 0.848 68 (36–84) 126 (52–156) 0.096
Serum creatinine (µmol/L) 100 (78–121) 192 (134–247) < 0.001 136 (115–201) 202 (137–247) 0.077
eGFR (mL/min/1.73 m2) 79 (67–91) 34 (31–46) < 0.001 41 (32–58) 34 (15–67) 0.266
Serum urea (mmol/L) 5.8 (5.2–6.4) 10.4 (8.4–12.7) < 0.001 9.3 (6.8–12.4) 9.9 (6.1–20.3) 0.632
Proteinuria/creatinine (mg/mmol) 2.7 (0.9–3.6) 9.4 (4.0–20.5) 0.008 6.0 (1.5–10.8) 20.5 (3.3–60.7) 0.029
Proteinuria/creatinine > 15 mg/mmol, n (%) 0 9 (39.1) 0.048 4 (17.4) 5 (71.4) 0.006
Diuresis (L/day) 1.4 (1.1–1.6) 1.4 (1.2–1.7) 0.811 1.4 (1.1–1.5) 1.6 (1.4–1.7) 0.033
Mean arterial pressure (mm Hg) 93 (93–103) 110 (103–116) 0.001 103 (93–116) 116 (103–116) 0.288
Treated hypertension, n (%) 1 (14.3) 14 (60.9) 0.031 10 (43.5) 5 (71.4) 0.195
  1. eGFR, estimated glomerular filtration rate; IL-2, interleukin 2; AR, acute rejection
  2. aMedian (interquartile range)